Analyst Soumit Roy of JonesTrading maintained a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report), retaining the price target of $40.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Soumit Roy has given his Buy rating due to a combination of factors surrounding ArriVent BioPharma, Inc.’s promising developments in their EGFR PACC mutated NSCLC program. The company is expected to release significant Phase 1b data soon, which could potentially align with the FDA for a registration pathway. Positive data could lead to a 15-20% increase in the company’s valuation, with a 70% probability of achieving a median progression-free survival (mPFS) of 11-13 months.
Additionally, the broader market’s recent positive response to favorable news in the healthcare sector suggests a supportive environment for ArriVent’s stock performance. Investors are particularly interested in the upcoming updates on long-term safety outcomes and pivotal trial designs, which could further enhance the company’s standing. The anticipated updates and potential for FDA alignment contribute to the optimistic outlook for ArriVent BioPharma, Inc., justifying the Buy rating.